When it comes to 5G, Houston is setting itself up as a leader within the United States. Getty Images

Last year, Houstonians Clayton and Emily Harris became the first commercial 5G customers. Now, a full year later, the Houston has a major seat at the table that's discussing the advancement of 5G technology.

At a forum on Tuesday, October 1, hosted by CTIA and the Center for Houston's Future, experts discussed Houston's role in the conversation about 5G. Here are some overheards from the morning event.

“We cannot take our leadership in 4G for granted as we transition to 5G.”

— Senator Ted Cruz. Cruz's keynote address warns of the United States resting on its laurels in the race to 5G. While the country had the edge on foreign competition for 4G, that doesn't mean 5G will have the same result, he says. In fact, Cruz cites multiple studies that show China and South Korea lead the race in 5G. Deloitte's research found that China has outspent the U.S. by $24 billion and has built 350,000 new sites, while the U.S. has built fewer than 30,000. The study also showed China is prepared to invest $400 billion. This information aside, Cruz tells the crowd that America has the ability to win the race to 5G.

“I think it’s a wonderful story to see how Texas has been leading the way.” 

— Brendan Carr, FCC commissioner. Carr references the Harris family, as well as other Texas cities he's visited that have been working hard to advance 5G. For Carr, expanding and implementing 5G is a huge opportunity for job creation. "The U.S. isn't the only country in the world that wants these jobs," he says to the crowd. "They're not the only country that wants to see the half a trillion dollars in economic growth that's going to come from this next-generation technology."

“I’ll admit, I’m an optimist, but there are significant challenges to making this 5G future a reality.”

— Jesse Bounds, director of innovation for the city of Houston. Bounds cited a few obstacles to overcome. There's a need for massive investment in infrastructure to blanket cities in 5G, and telecom companies are expected to spend $8 billion over the next five years to build this infrastructure, and cities too will need to invest in smart city technology. Consumers will need to pay more for data, and US consumers pay some of the highest rates in the world already. Not to mention the fact that a third of Americans don't have access to home internet. "As we build the infrastructure of the future, we must do so in a way that closes the digital divide so that those Americans can enjoy the same level of opportunity and prosperity that we do," Bounds says.

"Houston’s 5G network performance is 17 times better than the 4G. That’s today, in the very early days of 5G.”

— Paul Challoner, vice president of network product solutions at Ericsson. Challoner tells the crowd that of course this affects speed of data transferring and that is a huge pro for the technology, but there are other important perks for 5G advancement. The tech also affects device density, meaning that, a very large city like Houston, might have issues in dense areas. 5G also improves connectivity in crucial situations, like in the case of a surgeon using a device during surgery. Lastly, Challoner mentioned 5G is the most advanced technology when it comes to cybersecurity.

"One area that I’m most excited about is all the things that we don't talk about. All the applications that haven't yet been imagined, that are being dreamt up by software developers in their dorm rooms."

— Mishka Dehghan, vice president of 5G development at Sprint. Dehghan points out that 10 years ago, no one could have imagined ride sharing, now that is a huge industry with developing technology thanks to mobile data usage. With with the onset of 5G, she says she can't wait to see what technology is created in the next 10 years.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.